SEC Form 4 · accession 0001209191-16-128276

Adamas Pharmaceuticals Inc · ADMS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Officer — Chief Executive Officer · Director · 10% Owner

Period of report

Jun 15, 2016

Accepted (ET)

Jun 16, 2016 · 6:03 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001328143

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jun 15, 2016	M	204,900	$1.875	A	263,658	D
Common Stock	holding	—	—		—	390,792	I	Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11
Common Stock	holding	—	—		—	80,000	I	Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Bridget Elise Went
Common Stock	holding	—	—		—	80,000	I	Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Cora Margaret Went

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F1	$1.875	Jun 15, 2016	M	204,900	D	—	Sep 12, 2016	Common Stock	204,900	0	D